A 12-year-old boy diagnosed with a rare muscle-wasting disease has recently commenced a life-altering NHS treatment following a period of uncertainty for his family.
Ben Clarke suffers from Duchenne Muscular Dystrophy (DMD), an aggressive genetic condition primarily affecting boys, leading to muscle deterioration over time. He is one of many patients benefiting from givinostat, an approved drug available through a special NHS program in specific Trusts.
Despite the positive development, Alex Clarke, Ben’s father, emphasized that the battle is ongoing, cautioning that other families may face tragic outcomes before accessing the same treatment. Describing Ben’s reaction upon learning about the drug approval, Alex shared with the Mirror, “The joy on his face was incredible. He is thrilled that the drug is now accessible, reporting no adverse effects and feeling remarkably well.”
Givinostat aims to slow disease progression and maintain muscle functionality, although its use is limited to ambulant boys only.
Initially diagnosed with DMD at the age of four in 2017, Ben’s parents sought medical advice when observing troubling symptoms. After an online search confirmed the diagnosis, Alex expressed the initial heartbreak upon learning that Ben’s life expectancy was limited to his 12th birthday.
Now aged 12, Ben attends school full-time, described by his father as a radiant presence wherever he goes. While he can still walk, Ben relies on a wheelchair for longer distances, and daily tasks have become increasingly challenging for him.
The family campaigned for over a year alongside Duchenne UK through the ‘Time is Muscle’ initiative to access givinostat, as Ben’s Trust initially did not participate in the early access program.
Alex stressed the urgency for reform in drug evaluation processes, highlighting the necessity for timely access to treatments for rare pediatric conditions like DMD to prevent unnecessary delays and ensure affected children benefit from medical advances.
He underscored the plight of families with non-ambulant sons, expressing hope for broader access to givinostat in the future to provide equal opportunities for all affected individuals.
The current system’s limitations were criticized by Alex, who emphasized the urgency of delivering therapies promptly to maximize benefits for non-ambulant boys facing muscle degeneration without access to proven treatments.